NCT05656989

Brief Summary

Periodontal ligament-associated protein-1 (PLAP-1) and sclerostin play an important role in the suppression of bone formation. Tumor necrosis factor-alpha (TNF-α) is an important proinflammatory cytokine involved in periodontal bone loss. This study aims to investigate gingival crevicular fluid (GCF) PLAP-1, sclerostin and TNF-α levels in individuals with periodontal disease. Totally 71 systemically healthy and non-smoker individuals consisting of stage 3 grade C periodontitis (n=23), gingivitis (n=24) and periodontally healthy (n=24) were enrolled. Periodontal status was evaluated by measuring the full-mouth clinical periodontal parameters. GCF PLAP-1, sclerostin and TNF-α total amounts were measured by ELISA. Data were analyzed using non-parametric statistical tests.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
71

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 20, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2021

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

December 8, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 20, 2022

Completed
Last Updated

December 20, 2022

Status Verified

December 1, 2022

Enrollment Period

8 months

First QC Date

December 8, 2022

Last Update Submit

December 8, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • GCF PLAP-1 levels

    ng

    24 hours after clinical periodontal measurements

  • GCF sclerostin levels

    ng

    24 hours after clinical periodontal measurements

  • GCF TNF-α levels

    ng

    24 hours after clinical periodontal measurements

Study Arms (3)

Stage 3 Grade C Periodontitis

Generalized S3GC periodontitis patients had PD ≥ 6 mm and interproximal CAL ≥ 5 mm and with radiographic alveolar bone loss extending at least to the middle third of the root at 30 % of the teeth or more. These patients showed no more than four teeth loss due to periodontitis. The percentage bone loss/age values in this group were \> 1.0

Other: Periodontal clinical measurements and GCF sampling

Gingivitis

Gingivitis patients exhibited PD ≤ 3 mm and no interproximal CAL or radiographic bone loss. These patients had BOP ≥ 30% of probe sites.

Other: Periodontal clinical measurements and GCF sampling

Periodontal health

Periodontally healthy controls had an intact periodontium or a reduced periodontium in a non-periodontitis patient (without interproximal CAL or radiographic bone loss). PD was ≤ 3 mm and BOP was \< 10 % in this group.

Other: Periodontal clinical measurements and GCF sampling

Interventions

Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.

GingivitisPeriodontal healthStage 3 Grade C Periodontitis

Eligibility Criteria

Age27 Years - 46 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

A total of 71 systemically healthy and never-smoker individuals (34 males and 37 females and; aged 27 to 46 years) were consecutively included for this cross-sectional study.

You may qualify if:

  • no history of smoking (determined by self-reporting)
  • had a minimum of 18 natural remaining teeth (excluding third molars).

You may not qualify if:

  • suffered from diabetes mellitus, rheumatoid arthritis, cardiovascular and respiratory system diseases, hepatic and renal failure, metabolic bone diseases, endocrine disorders, immunologic and mucocutaneous diseases
  • used immunosuppressive agents, antibiotics, anti-inflammatory and anti-resorptive drugs, topical antiseptic solutions, calcium channel blockers, beta-blockers, anticoagulants and hormonal contraceptives within the past 3 months
  • pregnant or lactating
  • received any periodontal intervention in the past year
  • used removable partial dentures or orthodontic appliances

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Adnan Menderes University, Faculty of Dentistry, Department of Periodontology

Aydin, 09100, Turkey (Türkiye)

Location

Related Publications (1)

  • Gur B, Afacan B, Cevik O, Kose T, Emingil G. Gingival crevicular fluid periodontal ligament-associated protein-1, sclerostin, and tumor necrosis factor-alpha levels in periodontitis. J Periodontol. 2023 Oct;94(10):1166-1175. doi: 10.1002/JPER.22-0750. Epub 2023 Apr 19.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Gingival crevicular fluid

MeSH Terms

Conditions

Periodontitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

  • Berkay Gür

    Aydin Adnan Menderes University

    PRINCIPAL INVESTIGATOR
  • Özge Çevik

    Aydin Adnan Menderes University

    PRINCIPAL INVESTIGATOR
  • Timur Köse

    İzmir Ege University

    PRINCIPAL INVESTIGATOR
  • Gülnur Emingil

    İzmir Ege University

    PRINCIPAL INVESTIGATOR
  • Beral Afacan

    Aydin Adnan Menderes University

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 8, 2022

First Posted

December 20, 2022

Study Start

September 20, 2020

Primary Completion

June 1, 2021

Study Completion

June 15, 2021

Last Updated

December 20, 2022

Record last verified: 2022-12

Locations